Treating chronic lymphocytic leukemia with thalidomide and lenalidomide

Bibliography

• Zenz T, Mertens D, Kuppers R, From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10(18):37-50
   PubMedGoogle Scholar
• Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010;481-8
   PubMedGoogle Scholar
• Zenz T, Mertens D, Dohner H, Stilgenbauer S. Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011;25(3):131-7
   PubMed Web of Science ®Google Scholar
• Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull 2008;87:49-62
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28(10):1756-65
   PubMed Web of Science ®Google Scholar
• Awan FT, Johnson AJ, Lapalombella R, Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2010;51(1):27-38
   PubMed Web of Science ®Google Scholar
• Gorgun G, Holderried TA, Zahrieh D, Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005;115(7):1797-805
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118(7):2427-37
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24(1):22-32
   PubMed Web of Science ®Google Scholar
• Laurenti L, Piccioni P, Tarnani M, Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia. Leuk Res 2007;31(2):253-6
   PubMedGoogle Scholar
• Ferrajoli A, Lee BN, Schlette EJ, Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111(11):5291-7
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Dmoszynska A, Kowal M, Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia 2009;23(10):1771-8
   PubMed Web of Science ®Google Scholar
• Aue G, Njuguna N, Tian X, Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009;94(9):1266-73
   PubMed Web of Science ®Google Scholar
• Idler I, Giannopoulos K, Zenz T, Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 2010;148(6):948-50
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW, Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163(1):380-6
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Hideshima T, Catley LP, Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103(5):1787-90
   PubMed Web of Science ®Google Scholar
• Schafer PH, Gandhi AK, Loveland MA, Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003;305(3):1222-32
   PubMed Web of Science ®Google Scholar
• Gorgun G, Ramsay AG, Holderried TA, E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA 2009;106(15):6250-5
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Andritsos L, Liu Q, Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010;115(13):2619-29
   PubMed Web of Science ®Google Scholar
• Herman SE, Lapalombella R, Gordon AL, The role of phosphatidylinositol 3-kinase-{delta} in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011;117(16):4323-7
   PubMed Web of Science ®Google Scholar
• Kay NE, Shanafelt TD, Call TG, N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2009;50(4):588-92
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Takeshita K, Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005;106(10):3348-52
   PubMed Web of Science ®Google Scholar
• Furman RR, Allen SL, Leonard JP, Thalidomide Is Active Alone and in Combination with Fludarabine in Fludarabine-Relapsed and Refractory Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts 2004;2004:104(11):4835
   Google Scholar
• Chanan-Khan A, Miller KC, Musial L, Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24(34):5343-9
   PubMed Web of Science ®Google Scholar
• Chen CI, Bergsagel PL, Paul H, Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 2011;29(9):1175-81
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Lawrence D, Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011;117(10):2127-35
   PubMed Web of Science ®Google Scholar
• Andritsos LA, Johnson AJ, Lozanski G, Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26(15):2519-25
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Gowda A, Joshi T, The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol 2009;144(6):848-55
   PubMedGoogle Scholar
• Wu L, Adams M, Carter T, lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008;14(14):4650-7
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Yu B, Triantafillou G, Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008;112(13):5180-9
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Badoux X, O'Brien S, The Combination of Lenalidomide and Rituximab Induces Complete and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts 2010;116(21):1395
   Google Scholar
• Brown JR, Abramson J, Hochberg E, A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia 2010;24(11):1972-5
   PubMed Web of Science ®Google Scholar
• Gaidarova S, Mendy D, Heise C, Lenalidomide Induces Capping of CD20 and Cytoskeleton Proteins to Enhance Rituximab Immune Recognition of Malignant B-Cells. ASH Annual Meeting Abstracts 2010;116(21):2845
   Google Scholar
• Wendtner CM. Lenalidomide in CLL: what is the optimal dose? Clin Adv Hematol Oncol 9(3):220-4
   PubMedGoogle Scholar
• Wendtner CM, Hillmen P, Mahadevan D, Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 31 August 2011; [Epub ahead of print]
   Google Scholar
• Badoux X, O'Brien S, Wierda WG, Combination of Ofatumumab and Lenalidomide In Patients with Relapsed Chronic Lymphocytic Leukemia: Initial Results of a Phase II Trial. ASH Annual Meeting Abstracts 2010;116(21):2464
   Google Scholar
• Mauro FR, Armiento D, Orlando S, Fludarabine, Cyclophosphamide and Lenalidomide (FCL) for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL): Results of the Dose-Finding Phase of the GIMEMA LLC606 Study. ASH Annual Meeting Abstracts 2010;116(21):1377
   Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009;27(30):5008-14
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wen S, Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011;118(13):3489-98
   PubMed Web of Science ®Google Scholar
• Aue G, Soto S, Valdez J, Phase II Trial of Pulse Dosed Lenalidomide In Previously Treated Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts 2010;116(21):1383
   Google Scholar
• Blum KA, Jones JA, Andritsos L, Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 2010;116(21):2472
   Google Scholar
• Flinn IW, Berdeja JG, Waselenko JK, Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 2010;116(21):2461
   Google Scholar